Global Health Headlines: Key Developments from Weight Loss Drugs to Bird Flu

This summary covers recent health news, including Eli Lilly's weight loss drug approval in China, IT outages affecting hospitals in Germany and England, a significant discount on Humira's rival drug, challenges posed by a global tech outage in Canada, U.S. bird flu cases, and more.

Eli Lilly has announced that its weight loss drug, tirzepatide, received approval from Chinese regulators, ramping up competition with Novo Nordisk in Asia. The company's shares increased by 1.6% to $862.39.

Two German hospitals in Luebeck and Kiel have canceled elective surgeries due to a global IT outage attributed to cybersecurity firm Crowdstrike. Meanwhile, England's NHS is facing disruptions in booking systems but maintains emergency services. The outage has hit multiple industries, affecting operations worldwide from airlines to banking.

In other news, Boehringer Ingelheim and GoodRx are partnering to offer a biosimilar version of Humira at a 92% discount. Canada's health infrastructure is also under strain due to the same global tech outage. The U.S. CDC confirmed additional bird flu cases in Colorado, while Abbott plans a major marketing push for its glucose monitoring device beyond the diabetes market. Brazil has halted some poultry exports due to Newcastle disease, and concerns are mounting over the disposal methods of bird flu-infected poultry.

(With inputs from agencies.)